scispace - formally typeset
L

Louis van Bloois

Researcher at Utrecht University

Publications -  42
Citations -  2938

Louis van Bloois is an academic researcher from Utrecht University. The author has contributed to research in topics: Antigen & Liposome. The author has an hindex of 25, co-authored 39 publications receiving 2586 citations. Previous affiliations of Louis van Bloois include Icahn School of Medicine at Mount Sinai & Eindhoven University of Technology.

Papers
More filters
Journal ArticleDOI

Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes.

TL;DR: Despite the instability of liposome-association of 3-oxo-C(12)-homoserine lactone and resveratrol, intravenous administration of these compounds inhibited tumor growth for approximately 70% in a murine tumor model, showing that simple solubilization can have important therapeutic benefits.
Journal ArticleDOI

A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets.

TL;DR: This study suggests that this newly developed pegylated paramagnetic fluorescently labeled liposomes may serve as a useful diagnostic tool to investigate pathological processes in vivo with MRI.
Journal ArticleDOI

Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics.

TL;DR: This study investigated the possibilities, limitations and comparability of NTA, tRPS and hFC for analysis of tumor cell-derived EVs and synthetic mimics and detailed the differences in absolute quantification of EVs and liposomes using the three technologies.
Journal ArticleDOI

Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis

TL;DR: A single IA administration of clodronate liposomes leads to macrophage depletion and decreased expression of adhesion molecules in the synovial lining in patients with longstanding RA, and its therapeutic potential is currently under investigation.
Journal ArticleDOI

A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.

TL;DR: A new model for xenogeneic GVHD (X-GVHD) by intravenous transfer of huPBMCs into RAG2-/- gammac-/- mice is developed, with a high human T-cell chimerism associated with a consistent development of XGVHD within 14 to 28 days and a total mortality rate of 85% shorter than 2 months.